Page last updated: 2024-11-07

lysyl-aspartyl-glutamyl-leucine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

lysyl-aspartyl-glutamyl-leucine: retains type II surface membrane proteins in the endoplasmic reticulum; RN refers to all (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID123910
MeSH IDM0199330

Synonyms (9)

Synonym
kdel sequence
lysyl-aspartyl-glutamyl-leucine
l-leucine, n-(n-(n-l-lysyl-l-alpha-aspartyl)-l-alpha-glutamyl)-
lys-asp-glu-leu
113516-56-6
DTXSID80921087
n-[4-carboxy-2-({3-carboxy-2-[(2,6-diamino-1-hydroxyhexylidene)amino]-1-hydroxypropylidene}amino)-1-hydroxybutylidene]leucine
(2s)-2-[[(2s)-4-carboxy-2-[[(2s)-3-carboxy-2-[[(2s)-2,6-diaminohexanoyl]amino]propanoyl]amino]butanoyl]amino]-4-methylpentanoic acid
(2s)-2-[[(2s)-4-carboxy-2-[[3-carboxy-2-[[(2s)-2,6-diaminohexanoyl]amino]propanoyl]amino]butanoyl]amino]-4-methylpentanoic acid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" This result is not altered by protease inhibitors, suggesting the fusion proteins are probably not cleaved prior to translocation of the toxic A chain and implying that the toxins can carry large passenger proteins into the cytoplasm, an observation with interesting potential for analytical and therapeutic chemistry."( Differences in cytotoxicity of native and engineered RIPs can be used to assess their ability to reach the cytoplasm.
Day, P; Girbes, T; Hernandez, R; Kelly, C; Lord, M; Robertus, JD; Steighardt, J; Suh, JK; Svinth, M, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (116)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's50 (43.10)18.2507
2000's43 (37.07)29.6817
2010's23 (19.83)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.53 (24.57)
Research Supply Index4.80 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (1.65%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other119 (98.35%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]